SJA72 / APITBIO, Samjin Pharma - LARVOL DELTA

ApitBio, CD171 Target Intractable Solid Tumor Antibody Registered as Patent in China and Eurasia [Google translation] (HIT News) - "ApitBio...announced on the 11th that its patent for an antibody targeting the tumor antigen 'CD171' (L1CAM) for the treatment of intractable solid cancer has been registered in China and Eurasia. With this patent registration, the company secures exclusive rights in a total of 4 countries, following the US and Japan, until 2043."

Patent • Oncology • Solid Tumor